NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Executive Summary
Does wide public health concern warrant flexibility in regulatory standards for safety claims? Advisory panel on cardiovascular risk of NSAIDs spotlights dual challenge of accurately determining drug risks and communicating risks in informative way.
You may also be interested in...
Pradaxa Medicare Study: Observing a Slow Attitude Change at FDA on Observational Studies
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.
NSAID Panel Could Give Naproxen Labeling Edge
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.